bdc-1001
bdc-1001: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Bolt Biotherapeutics, Inc. (BOLT)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | Phase 1/Phase 2 |
Clinical Trials (1)
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors
Frequently asked questions
Who is developing bdc-1001?
bdc-1001 is being developed by Bolt Biotherapeutics, Inc..
How many clinical trials involve bdc-1001?
BioSniper tracks 1 clinical trial involving bdc-1001.
Analyze Bolt Biotherapeutics, Inc. & bdc-1001 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company